Frågan gäller etiologi till och behandling av malign hypertermi.

Fråga: Frågan gäller etiologi till och behandling av malign hypertermi.

Sammanfattning: Frågeställaren har tagit del av nedanstående litteratursökning. Var god se utförlig litteratursammanställning samt bifogade medicinska kommentar.

Svar: Se sammanfattning/konklusjon. 1 Ally AI, Horrobin DF, Manku MS, Morgan RO, Karmazyn M, Karmali RA, Gunnane SC: Dantrolene blocks intracellular calcium release in smooth muscle: competitive antagonism of thromboxane A2. Can J Physiol Pharmacol 1978; 56: 520-523 2 Anderson IL: Use of dantrolene sodium in malignant hyperthermia. Drug Therapy 1977; 7: 106 3 Avery GS (ed): Drug treatment, 2nd ed, Sydney och New York, Adis Press 1980 4 Bronstein SL, Ryan DE, Solomons CC, Mahowald MC: Dantrolene sodium in the management of patients at risk from malignant hyperthermia. J Oral Surg 1979; 37: 719-724 5 Clinical monograph. Dantrolene sodium. The first drug therapy specific for life-threatening malignant hyperthermia. Norwich-Eaton Pharmaceuticals 1979 6 Dantrolene sodium approved for malignant hyperthermia. FDA Drug Bulletin 1979; 9: 27 7 Ellis FR, Cain PA, Harriman DGF: Multifactorial inheritance of malignant hyperthermia suspectibility. I: The second international symposium on malignant hyperthermia (eds Aldrete JA, Britt BA). New York, London: Grune & Stratton: 1973 pp. 329-338 8 Ellis FR, Harriman DGF, Currie S, Cain PA: Screening for malignant hyperthermia in suspectible patients. I: The second international symposium on malignant hyperthermia (eds Aldrete JA, Britt BA) New York, London: Grune & Sratton 1973 pp. 273-285 9 Faust DK, Gergis SD, Sokoll MD: Management of suspected malignant hyperpyrexia in an infant. Anesth Analg 1979; 58: 33-35 10 Flewellen EH, Nelson TE: Dantrolene dose response in malignant hyperthermia (MHS) swine: method to obtain prophylaxis and therapeutics. Anesthesiology 1980; 52: 303-308 11 Francis KT, Hamrick ME: Dantrolene inhibition of the hepatic mixed function oxidase system. Res Commun Chem Pathol Pharmacol 1979; 23: 69-89 12 Free CW, Jaimon MPC: Pre-anaesthetic administration of dantrolene sodium to a patient at risk from malignant hyperthermia: case report. New Z Med J 1978; 88: 493-494 13 Friesen CM, Brodsky JB, Dillingham MF: Successful use of dantrolene sodium in human malignant hyperthermia syndrome: A case report. Canad Anaesth Soc J 1979; 26: 319-321 14 Goodman LS, Gilman A (ed): The pharmacological basis of therapeutics. 5th ed. New York: MacMillan Publishing Co Inc. 1979 15 Gronert GA, Milde JH, Theye RA: Dantrolene in porcine malignant hyperthermia. Anesthesiology 1976; 44: 488-495 16 Hallen B, Swensson SA: Hypertermi, muskelspasm och metabolisk acidos vid generell anestesi. Läkartidningen 1967; 64: 4687-4691 17 Harriman DGF, Ellis FR, Franks AJ, Sumner DW: Malignant hyperthermia myopathy in man: an investigation of 75 families. I: The second international symposium on malignant hyperthermia. (eds Aldrete JA, Britt BA) New York, London: Grune & Stratton 1978 pp 67-87 18 Jessen K, Hansen E, Kratholm S, Lunding M, Ording H, Mogensen JV: Malign hypertermi. Ugeskr Laeger 1978; 140: 95-99 19 Johansson BW: Temperaturregulation och feber. Tika information 1980; 1: 4-8 20 Kerr DD, Wingard DW, Gatz EE: Prevention of porcine malignant hyperthermia by oral dantrolene. I: Second International symposium on malignant hyperthermia (eds Aldrete JA, Britt B). New York: Grune & Stratton 1978 pp 499-507 21 Kikuchi H, Morio M, Shinozaki M, Ishihara S: Statistical considerations of malignant hyperthermia in Japan. I: Second International symposium on malignant hyperthermia (eds Aldrete JA, Britt B). New York: Grune & Stratton 1978 pp 483-493 22 Lee JA, Atkinson RJ: Hyperpyrexia. I: A synopsis of anaesthesia. 7th ed. Bristol: John Wright & Sons Ltd 1973 pp 824-827 23 Martz RC, Kolb EM: Dantrium in malignant hyperthermia. Drug Intell Clin Pharmacy 1979; 13: 297-298 24 Meyler WJ, Mols-Thyrkow I, Scaf HJA, Sargo J, Wsseling H: The effect of dantrolene sodium on rat skeletal muslce in relation to the plasma concentration. Eur J Pharmacol 1979; 53: 335-342 25 Moulds RFW, Denborough MA: Biochemical basis of malignant hyperpyrexia. Br Med J 1974; 2: 241-244 26 Nelson TE, Flewellen EH: Rationale for dantrolen vs procainamide for treatment of malignant hyperthermia. Anesthesiology 1979; 50: 118-122 27 Pandit SK, Kothary SP, Cohen PJ: Orally administered dantrolene for prophylaxis of malignant hyperthermia. Anesthesiology 1979; 50: 156-158 28 Pinder RM, Brogden RN, Speight TM, Avery GS: Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977; 13: 3-23 29 Utili R, Boitnott JK, Zimmerman HJ: Dantrolene - associated hepatic injury. Gastroenterology 1977; 72: 610-616 30 Vallner JJ, Honigberg IL, Stewart JT, Peyton AB: Dantrolene and metabolite levels in six patients on chronic therapy. Curr Therap Res 1979; 25: 79-91 31 Ökad kännedom mäste spridas om profylax och behandling av malign hypertermi. Läkartidningen 1974; 71: 1869-1870 32 Alvan G, Gustafsson LL: Ny behandlingsmöjlighet vid malign hypertermi. Läkartidningen 1980; 77: 4842-4843